- Conditions
- Coronary Disease
- Interventions
- placebo, dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Clearwater, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- dabigatran etexilate mesylate
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
- Interventions
- Dabigatran Etexilate Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Coronary Artery Disease
- Interventions
- Dabigatran, Placebo
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Behavioral · Drug · Procedure
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 3,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
- Interventions
- Dabigatran Etexilate Mesylate, Quizartinib
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Atrial Fibrillation, Percutaneous Coronary Intervention
- Interventions
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
- Conditions
- Atrial Fibrillation
- Interventions
- Dabigatran etexilate (Pradaxa)
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Atrial Fibrillation
- Interventions
- Warfarin, Dabigatran Etexilate 150mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Fremont, California • Sacramento, California + 17 more
- Conditions
- Thromboembolism
- Interventions
- Warfarin, Dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
- Conditions
- Atrial Fibrillation, Cerebrothromboembolus, Neurocognitive Function
- Interventions
- Atrial Fibrillation Ablation
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Pancreatitis
- Interventions
- Dabigatran Etexilate Mesylate, Standard of Care
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida